Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

The Guardian - UK

New type of jab helps to maintain weight loss

New type of jab helps to maintain weight loss

Experts have developed a new drug which helps tackle the underlying causes of obesity.

The Independent UK

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years

GSK plc (NYSE:GSK) on Wednesday announced plans to invest $30 billion across the United States in research and development and supply chain infrastructure over the next five years.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss?

Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a weight-related medical problem, and without diabetes.

This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

NHS staffer now forced to work extra shifts to cover cost of Mounjaro

Carly Stokes, who has dropped 6st in a year using the weight-loss jab, will now have to pay £319 a month

The Independent UK

Vital breakthrough as once-a-day pill can help people lose ‘significant’ weight

A fifth of people taking the weight-loss tablet Orforglipron lost 20 per cent of their body weight

The Independent UK

inkl

Read news from The Economist, FT, and more,
with one subscription

Daily weight loss pill can help cut body weight by a fifth, trial shows

Daily weight loss pill can help cut body weight by a fifth, trial shows

One in five people who took orforglipron once a day for 72 weeks lost 20% or more of their weight, maker Eli Lilly says

The Guardian - UK

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. (NYSE:LLY), is false or misleading.

Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing

Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing

Eli Lilly and Co. (NYSE:LLY) announced on Tuesday that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County.

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment

Novo Nordisk A/S (NYSE:NVO) reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. (NYSE:LLY).

Big pharma firms have paused nearly £2bn in UK investments this year

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

The Guardian - UK

Pharma Giant Eli Lilly (LLY) Could Still Be a Screaming Deal—Here’s the Statistical Evidence

Pharma Giant Eli Lilly (LLY) Could Still Be a Screaming Deal—Here’s the Statistical Evidence

Although healthcare juggernaut Eli Lilly has struggled for momentum this year, the latest unusual options activity for LLY stock could point to potential upside.

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit

The U.K.-based AstraZeneca Plc (NASDAQ:AZN) paused a planned 200 million pounds ($271.26 million) investment in its Cambridge research site.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Urgent warning over illegal weight loss jabs ‘not approved for humans’ offered for sale on TikTok

Exclusive: TikTok sellers purporting to sell the ‘Triple G’ of weight loss jabs have had their accounts pulled after The Independent exposed them to the social media giant

Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case

A federal appeals court has upheld a $183.7 million judgment against Eli Lilly and Co. (NYSE:LLY), rejecting the drugmaker's attempt to overturn a whistleblower lawsuit that accused it of defrauding Medicaid.

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies

The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.

Get all your
news in one place.

100's of premium titles.
One news app.

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY).

The Guardian - UK

Wegovy maker Novo Nordisk to cut 9,000 jobs amid increased competition

Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly

Defiance Has A New ETF For High-Stakes Pharma Traders

Defiance ETFs launched its newest leveraged product on Sept. 3, the Defiance Daily Target 2X Short LLY ETF (NASDAQ:LLYZ). The new fund is designed for traders seeking to short pharmaceutical giant Eli Lilly and Co (NYSE:LLY).

Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data

Eli Lilly and Co. (NYSE:LLY) on Tuesday launched Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform that provides biotech companies access to drug discovery models trained on years of Lilly’s research data.

Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus chemoimmunotherapy (bendamustine plus rituximab), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions.

Ozempic Is The New Botox And Big Pharma Is Printing Billions

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass $150 billion…

The Independent UK

UK ‘will be one of the first countries’ to get new weight-loss pill

1 … 7 8 9 10

People

190,441 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

The Independent

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

375,326 stories

139,309 stories

The United States

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play